Silence Therapeutics designs RNA-based drugs that silently switch off disease-causing genes in the liver, like a genetic dimmer switch for conditions such as high cholesterol and blood disorders.
The company currently earns minimal revenue (GBP 0.04B in 2024) from collaborations, but spends heavily on R&D, resulting in net losses (GBP -0.05B in 2024). Money primarily comes from partnership upfronts and milestones, not product sales.
Its proprietary mRNAi GalNAc platform is patented and validated by partnerships with AstraZeneca and Hansoh Pharmaceutical, creating barriers to entry. However, large competitors like Alnylam and Moderna have similar or advanced RNAi platforms, and Silence's t
Key events, in time order
None yet
None yet
The discussion centers on the timing of Silence Therapeutics' data release relative to a PDUFA date, suggesting a potential catalyst for the stock.
Main discussion
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
